What medicine is used for aplastic anemia?

Written by Li Fang Fang
Hematology
Updated on September 21, 2024
00:00
00:00

Aplastic anemia, whether acute or chronic, primarily uses immunosuppressive agents and hematopoietic stimulants for treatment. Cyclosporine is commonly used clinically among immunosuppressants, while the medicines stimulating bone marrow hematopoiesis mainly include androgens such as danazol and stanozolol. These medications all have associated adverse reactions: immunosuppressants can lead to hypertension, hyperglycemia, impaired liver and kidney function, and gum hypertrophy, while the main adverse reactions of hematopoietic androgens are liver damage. (Please use medications under the guidance of a doctor.)

Other Voices

doctor image
home-news-image
Written by Li Fang Fang
Hematology
59sec home-news-image

Is aplastic anemia contagious?

Aplastic anemia is not contagious and has a minor hereditary factor, meaning that if a family member has aplastic anemia, it is generally not inherited by the next generation. The cause of aplastic anemia is still unclear, but possible reasons include: 1. Damage to hematopoietic stem cells. After the hematopoietic stem cells are damaged, it leads to limited stem cell proliferation and reduced hematopoiesis. 2. Damage to the hematopoietic microenvironment. Damage to the hematopoietic microenvironment can lead to changes that disrupt the regeneration of hematopoietic stem cells. 3. Immune factors. Immune factors can cause immune damage, directly damaging hematopoietic stem cells, thereby causing bone marrow regeneration disorders.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
52sec home-news-image

How long can one live with aplastic anemia?

The lifespan of patients with aplastic anemia depends on the type and the effectiveness of the treatment. Aplastic anemia is classified into acute aplastic anemia and chronic aplastic anemia. In cases of acute aplastic anemia, cure is possible through intensified immunotherapy or hematopoietic stem cell transplantation; however, without aggressive treatment, the survival period is relatively short, generally not exceeding one year. Chronic aplastic anemia, on the other hand, has a longer medical history, and patients can often live for ten to twenty years or more. However, throughout this period, ongoing transfusions of red blood cells and platelets are required to support treatment.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
51sec home-news-image

Can aplastic anemia have children?

Acute aplastic anemia, after effective immunotherapy and discontinuation of medication for more than two years, or after hematopoietic stem cell transplantation and discontinuation of medication for more than two years, it is possible to have children. In cases of chronic aplastic anemia, due to long-term oral intake of immunosuppressants and hematopoietic stimulants, having children is not advised. However, if immunosuppressants and hematopoietic drugs are effective and discontinued for more than two years, and blood levels are acceptable, then it is possible to have children.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
50sec home-news-image

Aplastic anemia is classified into several types.

Aplastic anemia is divided into two types: acute aplastic anemia and chronic aplastic anemia. Acute aplastic anemia presents suddenly and is severe. Treatment requires intensified immunotherapy or suppression of hematopoietic stem cell transplantation. Chronic aplastic anemia develops slowly, has a longer history, and is relatively less severe. The treatment for chronic aplastic anemia mainly involves immunotherapy combined with therapy to promote hematopoiesis. In addition, regardless of the type, all cases of aplastic anemia require regular complete blood count checks and, when necessary, supportive treatment with red blood cell and platelet transfusions.

doctor image
home-news-image
Written by Li Fang Fang
Hematology
49sec home-news-image

The main cause of aplastic anemia is.

The causes of aplastic anemia are considered to be of three types: abnormalities in hematopoietic stem cells, abnormalities in the bone marrow microenvironment, and abnormalities in immune factors. Among these, abnormalities in immune factors play a dominant role. Therefore, most patients with aplastic anemia see some improvement after receiving immunosuppressive therapy clinically. However, there is a small subset of patients with aplastic anemia for whom immunosuppressive therapy is not effective, and the causes of the disease in these patients are not well understood and may be congenital, such as congenital dyskeratosis.